Tissue Regenix
Regenerative medicine using decellularized tissue scaffold technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | £14.6m | Post IPO Equity | |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 2 % | (14 %) | 24 % | 20 % | (3 %) | (23 %) | 9 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (27 %) | (15 %) | (4 %) | 2 % | 5 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (76 %) | (24 %) | (11 %) | (6 %) | (2 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | - | - | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Tissue Regenix is a medical technology company specializing in regenerative medicine. Founded in 2006 as a spin-out from the University of Leeds, the company commercializes academic research to develop treatments that harness the body's innate ability to heal. The firm operates globally, with a significant presence in the United States and Europe.
The company was founded to commercialize the research of its partners. Antony Odell served as CEO from 2008 until his resignation in 2017. Daniel Lee, who has nearly 30 years of experience in the medical device and biologics industry, was appointed CEO in November 2020. He previously held leadership roles at CellRight Technologies, Scaffold Biologics, and Aperion Biologics, and began his career in R&D at U.S. Surgical Corporation (now Medtronic).
Tissue Regenix's business model is centered around its proprietary platform technologies: dCELL® and BioRinse®. The dCELL® technology removes cellular material from animal and human soft tissue to create an acellular scaffold that is not rejected by the patient's body and can be used to repair damaged body parts. The BioRinse® platform provides sterile bone and soft tissue allografts. The company generates revenue through the commercialization of a portfolio of 12 product lines, serving surgical applications in orthopedics, spine, dental, and wound care. It employs a hybrid commercial model, utilizing direct sales, a network of distributors, and strategic partnerships. A key milestone was the acquisition of CellRight Technologies® in 2017, a biotech company specializing in osteoinductive and wound care scaffolds, which expanded Tissue Regenix's manufacturing capabilities and presence in the U.S. market.
Keywords: regenerative medicine, medical technology, decellularization, tissue scaffold, dCELL technology, BioRinse technology, allografts, orthopedics, wound care, sports medicine, soft tissue repair, bone regeneration, osteoinductive, surgical biologics, cellright technologies, biosurgery, dental biomaterials, human tissue, xenograft, acellular dermis
Tech stack
Investments by Tissue Regenix
Edit